Month: June 2021

Release – Great Bear Strengthens Management Team and Provides Update on Regional Projects

Posted on by Admin


Great Bear Strengthens Management Team and Provides Update on Regional Projects

 

May 31, 2021 – Vancouver, British Columbia, Canada – Great Bear Resources Ltd. (the “Company” or “Great Bear”, TSX-V: GBR; OTCQX: GTBAF) today announced key management appointments.  The Company concurrently announces the departures of Mr. Robert Scott, Chief Financial Officer; Mr. Jeff Dare, Corporate Secretary; and Mr. Tony Ricci, who, after serving for more than 10 years, will be retiring from the Board of Directors and is not standing for re-election at the upcoming Annual General Meeting on June 29th.  In addition, the Company announces the acceleration of option payments on three of its regional projects, completing the required earn-ins.  All regional Red Lake area projects are now 100% owned by Great Bear.

“I would like to sincerely thank Mr. Scott, Mr. Dare, and Mr. Ricci for their significant contributions over the past number of years to Great Bear.  Each of them was instrumental to the success of the Company and I look forward to following their ongoing contributions within our industry,” said Chis Taylor, President and CEO of Great Bear.  “The management appointments we are making today significantly enhance our team’s skillset and will be key to Great Bear’s future success as we continue to advance our flagship Dixie Project.”

Management Appointments

Calum Morrison, Vice President, Business Development & Chief Financial Officer

Calum Morrison has been leading Corporate Development at Great Bear since 2019, a period in which the Company has experienced exceptional growth. In addition to his Corporate and Business Development responsibilities, Mr. Morrison has been appointed Chief Financial Officer with an effective date of May 26th.  Mr. Morrison has over 15 years of experience in the mining industry, having worked in corporate development, investment banking, and accounting roles. Mr. Morrison is a Chartered Professional Accountant (CPA, CA), and a Chartered Financial Analyst (CFA) and holds a B.Sc. degree in Environmental Science from Dalhousie University.

Andrea Diakow, Vice President, Projects

Andrea Diakow has been a key contributor to Great Bear’s exploration success at the Dixie Project since 2017.  Ms. Diakow is a professional geologist with over 15 years of experience working in the mineral exploration industry on diverse precious and base metal projects ranging from grassroots to feasibility stage. Her experience includes over 6 years of gold exploration in the Red Lake district.  Employing her strong technical background and diverse experience, Mrs. Diakow manages Great Bear’s exploration program, including QA/QC practices, and directs the various advanced exploration studies that are currently being undertaken at Dixie.  Ms. Diakow holds a B.Sc. degree in Geology from the University of Calgary and is a P.Geo.

Jenni Piette, Director, Sustainability and Stakeholder Relations

Jenni Piette has over 10 years of experience in mining investor relations and corporate communications. Most recently, Ms. Piette served as Head of Investor Relations at GT Gold, where she managed the investor relations strategy in addition to community and stakeholder consultation.  Prior to joining GT Gold, she served as Manager of Investor Relations at Teranga Gold Corporation through 2018 and at Richmont Mines, until the sale of the company to Alamos Gold in November 2017.  Ms. Piette began her career in investor relations at Detour Gold Corporation in 2012, prior to which she served as a contracted mining and earth science outreach educator for PDAC Mining Matters.  Ms. Piette holds a B.Sc. with Distinction in Geology/Ecology from Concordia University and is a Certified Professional in Investor Relations under CIRI/Ivey School of Business.

Darryl Boyd, Director, Environment

Darryl Boyd has been employed in the mining sector for 24 years, holding roles related to planning, permitting, and developing projects in Ontario from early exploration to commercial production.  Mr. Boyd has managed baseline studies, engineering designs, permitting, community engagement, energy supply, land tenure and a variety of operational duties related to environmental management.  Examples of his significant project experience includes: The McCreedy Mine (FNX Mining), Timmins West (Lakeshore Gold), Lac Des Iles Mine (North American Palladium), Lockerby Mine (First Nickel), and the Sugar Zone Mine (Harte Gold).  Mr. Boyd holds a B.Sc. degree in Environmental Science from the University of Guelph and a Certificate in Environmental Assessment from Lakehead University.

Cori Compton, Corporate Secretary

Ms. Compton has over 20 years of corporate secretarial, corporate governance and securities regulatory experience, 10 of which are specifically with public companies in the mining industry.  Ms. Compton has performed the Corporate Secretary function for a number of publicly listed companies, including Pan American Silver, Silver Standard Resources (now SSR Mining), Wildcat Silver (predecessor to Arizona Mining), and Ventana Gold Corp.  Ms. Compton is a member of both the BC Paralegal Association and the Canadian Society of Corporate Secretaries.

Update on Regional Properties

The Company is also pleased to announce that it recently paid an aggregate of $180,000 to accelerate its earn-ins for its regional Red Lake projects (Pakwash, Sobel, and Red Lake North), and also gave notice of its intention to terminate its option on the Dedee Property.

Great Bear now holds a 100% interest in it’s Red Lake Properties (Dixie, Pakwash, Sobel and Red Lake North), totalling 200 km2 of prospective mineral claims.  At this time, there are no changes to the previously announced 2021 exploration budget, which is majority focused on a multi-rig drill program at its flagship Dixie Project, but also includes field investigations and target definition at all regional properties.

June 7th Webinar

The Company reminds interested shareholders that a webinar will take place on Monday, June 7th at 11:00 am PDT / 2:00 pm EDT. Management will be available to answer questions following the presentation. Online registration and participation details may be found at the following link:

https://us02web.zoom.us/webinar/register/WN_MJNWX5GERvKjZ63Jh89n_Q

For those unable to participate, a recording of the webinar will be posted to the Company’s web site following the live broadcast.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 200 km2 of highly prospective tenure across four projects: the flagship Dixie Project (100% owned), the Pakwash Property (100% owned), the, the Sobel Property (100% owned), and the Red Lake North Property (100% owned) all of which are accessible year-round through existing roads.

ON BEHALF OF THE BOARD

“Chris Taylor”

Chris Taylor, President and CEO

Investor Inquiries:
Mr. Knox Henderson
Tel: 604-646-8354
Direct: 604-551-2360
info@greatbearresources.ca
www.greatbearresources.ca

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Release – PDS Biotech to Host Oncology RD Day on June 16 2021

Posted on by Admin

 


PDS Biotech to Host Oncology R&D Day on June 16, 2021

 

FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community from 8:00 – 10:00 AM ET on Wednesday, June 16th.

PDS Biotech’s Oncology R&D Day will focus on the Company’s advancements in its ongoing preclinical and clinical work and will feature presentations from:

  • Dr. Frank Bedu-Addo, President and CEO, PDS Biotech
  • Dr. Lauren V. Wood, Chief Medical Officer, PDS Biotech
  • Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health
  • Dr. Julius Strauss, Principal Investigator, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health
  • Dr. Caroline Jochems, Staff Scientist, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health

A copy of the presentations will be available on June 17th on the scientific presentations and publications page of PDS Biotech’s website. Registration for PDS Biotech’s Oncology R&D Day is now open and a live webcast of the event will be available online in the investor relations section of the company’s website at https://pdsbiotech.com/investors/news-center/events. A replay will be available on the company website for 90 days following the webcast.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products may overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple investigational therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The company’s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital

The GEO Group, Inc. (GEO) – Is the Debt Downgrade Warranted?

Posted on by Admin

Tuesday, June 01, 2021

The GEO Group, Inc. (GEO)
Is the Debt Downgrade Warranted?

With over 94,000 beds owned, leased or managed across its business lines and serving over 260,000 people daily, GEO is a leading provider of mission critical real estate to its governmental partners. The Company is the first fully integrated equity REIT specializing in the design, financing, development, and operation of secure facilities, processing centers, and community reentry centers in the U.S., Australia, South Africa, and the U.K.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    S&P Downgrade. Last week, S&P downgraded GEO Group to CCC+ from B. Senior secured debt was lowered to B from BB- and senior unsecured debt was dropped to CCC from B-. The ratings agency cited weaker and “increasingly complex” operating conditions, significant debt maturities in 2024, unsupportive capital markets, and the hiring of “restructuring advisors,” among the reasons for the downgrade.

    But What Has Changed? Not much, in our opinion, since S&P’s previous downgrade in March.  Yes, GEO announced the hiring of Skadden Arps and Lazard to assist with the review of various capital structure alternatives, but we view this step as prudent management by the BoD and would note that CoreCivic took exactly the same measures last year when that Company performed its capital structure review …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.